Cargando…
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new ang...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910761/ https://www.ncbi.nlm.nih.gov/pubmed/35269766 http://dx.doi.org/10.3390/ijms23052625 |
_version_ | 1784666582098640896 |
---|---|
author | Munawar, Nayla Ahmad, Aftab Anwar, Munir Ahmad Muhammad, Khalid |
author_facet | Munawar, Nayla Ahmad, Aftab Anwar, Munir Ahmad Muhammad, Khalid |
author_sort | Munawar, Nayla |
collection | PubMed |
description | Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new angle to look at the potential causes and treatment options for schizophrenia. Because of the number of side effects, including gut dysbiosis, of traditional antipsychotic drugs, new alternative therapeutic options are under consideration. We propose that non-pharmacotherapy using biotherapeutic products could be a potent treatment to improve cognitive impairment and other symptoms of schizophrenia. Use of live microorganisms (probiotics), fibers (prebiotics), and polyphenols alone or in a mixture can maintain gut microbial diversity and improve the two-way relationship of the gut microbiota and the central nervous system. Fiber and polyphenol induced management of gut microbiota may positively influence the gut–brain axis by increasing the level of brain-derived neurotrophic factors involved in schizophrenia. Furthermore, we endorse the need for comprehensive clinical assessment and follow-up of psychobiotic (pro and prebiotics) treatment in mental illness to estimate the level of target recovery and disability reduction in schizophrenia. |
format | Online Article Text |
id | pubmed-8910761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89107612022-03-11 Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia Munawar, Nayla Ahmad, Aftab Anwar, Munir Ahmad Muhammad, Khalid Int J Mol Sci Review Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new angle to look at the potential causes and treatment options for schizophrenia. Because of the number of side effects, including gut dysbiosis, of traditional antipsychotic drugs, new alternative therapeutic options are under consideration. We propose that non-pharmacotherapy using biotherapeutic products could be a potent treatment to improve cognitive impairment and other symptoms of schizophrenia. Use of live microorganisms (probiotics), fibers (prebiotics), and polyphenols alone or in a mixture can maintain gut microbial diversity and improve the two-way relationship of the gut microbiota and the central nervous system. Fiber and polyphenol induced management of gut microbiota may positively influence the gut–brain axis by increasing the level of brain-derived neurotrophic factors involved in schizophrenia. Furthermore, we endorse the need for comprehensive clinical assessment and follow-up of psychobiotic (pro and prebiotics) treatment in mental illness to estimate the level of target recovery and disability reduction in schizophrenia. MDPI 2022-02-27 /pmc/articles/PMC8910761/ /pubmed/35269766 http://dx.doi.org/10.3390/ijms23052625 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Munawar, Nayla Ahmad, Aftab Anwar, Munir Ahmad Muhammad, Khalid Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title | Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title_full | Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title_fullStr | Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title_full_unstemmed | Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title_short | Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia |
title_sort | modulation of gut microbial diversity through non-pharmaceutical approaches to treat schizophrenia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910761/ https://www.ncbi.nlm.nih.gov/pubmed/35269766 http://dx.doi.org/10.3390/ijms23052625 |
work_keys_str_mv | AT munawarnayla modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia AT ahmadaftab modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia AT anwarmunirahmad modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia AT muhammadkhalid modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia |